Enteral Feeding Formulas Market Size, Share & Trends Analysis Report By Product, By Flow Type, By Stage, By Indication, By End-user, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global enteral feeding formulas market size was valued at USD 6.4 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 5.6% from 2022 to 2030. An increase in the incidence of chronic diseases and a rise in the aging population that are at high risk of several life-threatening disorders, such as cardiovascular disease, diabetes, cancer, liver failure, and renal failure, are among the major factors anticipated to drive the adoption of enteral feeding formulas and thus accelerate market growth over the forecast years. For instance, according to the Centers for Disease Control and Prevention (CDC), approximately 85% of older adults are living with at least one chronic disease, and 65% present two.

In addition, the increase in the number of premature births is further fueling the adoption of enteral feeding formulas to cater to the nutritional requirement of newborns, which, in turn, is expected to drive the market over the years. An increase in the prevalence of malnutrition associated with higher ICU mortality is one of the major factors driving the adoption of enteral feeding formulas. Although malnutrition is considered a common under-treated and under-recognized condition globally, the associated mortality rate is very high in some regions of the world. For instance, according to WHO, about 45% of deaths of children below 5 years occur due to malnutrition, with the death rate being higher in low- and middle-income countries.

In addition, enteral nutrition is the most preferred way of feeding infants who are vulnerable to disease and death due to undernutrition and deficiencies in vitamins and minerals. Moreover, an increase in awareness about the advantages of early enteral feeding, which reduces septic and non-septic complications and improves clinical outcomes of critically ill and injured patients is expected to boost market growth over the years.

In addition, an increase in product launches and product development by manufacturers is one of the key factors driving the market. For instance, Victus, Inc. in 2020 launched specialized nutrition for daily immune support, “Abintra Care,” with a combination of key nutrients, such as vitamin C, antioxidants, zinc, and selenium.

Moreover, a rise in the number of manufacturers due to high demand for enteral nutrition formulas for elderly people at home will boost the market growth. Nursing care and home health agencies also prefer enteral feeding formulas for post-surgery patients, which drives the industry’s expansion. Also, increase in the number of neonatal intensive care units is expected to propel growth.

Furthermore, technological advancements and product innovations are anticipated to drive the market during the forecast period. Key players are focusing on expanding their product portfolio by designing advanced medical devices to deliver enteral nutrition and meet the demands of patients under treatment in homecare settings and intensive care units.

For instance, Witleaf in November 2021 launched the Brio-Enteral Nutrition Pump (EFP), which is an easy-to-use rotary peristaltic pump that helps in easy delivery of enteral nutrition.  The device is equipped with sound and light alarm functionality to alert the user in case of pipeline blockage or insufficient battery voltage, thus making this device safe and accurate.

Rapid increase in COVID-19 cases coupled with an increase in the number of patients admitted to ICU due to coronavirus infection and severe chronic health conditions further increases the adoption of enteral nutrition, which boosts the growth. In addition, the rise in elderly population suffering from several chronic conditions and eating disorders, such as dysphagia, diabetes, cancer, etc., treated in homecare settings to avoid the risk of COVID-19 infection drives the adoption of enteral nutrition formulas.

COVID-19 Enteral Feeding Market Impact: 8.3% Increase In Revenue Growth from 2019 to 2020

For instance, the guidelines published by the Society of Critical Care Medicine and the American Society for Parenteral and Enteral Nutrition in April 2020 recommended early enteral nutrition for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients within 24–36 hours of admission to the ICU. Such guidelines by healthcare authorities thus led to an increase in the adoption of enteral feeding formulas during the pandemic. 

Product Insights

Based on product type, standard formulas dominated the market with a share of 53.7% in 2021. This high share of the segment can be attributed to the wide adoption of standard formulas among all types of patients and associated cost-effectiveness. In addition, the easy availability of polymeric nutritional complete formulas, which are suitable for use in both hospitals and home care settings, is also anticipated to accelerate segment growth over the years. Moreover, high preference and recommendations by physicians to consume standard formulas for gastrostomy tube (G-tube) patients to enhance children’s nutrition are supporting the growth.

Furthermore, the disease-specific formulas segment is expected to grow at the fastest rate due to an increase in the prevalence of several chronic disorders, such as diabetes, cancer, and cardiovascular diseases. In addition, the increase in the development and launch of disease-specific nutritional products by manufacturers as per the patient's needs has further accelerated segment growth. An increase in the adoption of disease-specific and immune-modulating formulas to manage several chronic diseases is also projected to boost the segment growth rate over the forecast period. 

Flow Type Insights

Based on flow type, intermittent feeding flow type in 2021 dominated the market with a high revenue share of 94.3%. This segment share can be attributed to an increase in intermittent enteral nutrition administration recommendations by physicians due to its better gastrointestinal tolerance by patients. Intermittent feeding improves whole-body protein synthesis, increases mesenteric arterial blood flow, and reduces blood glucose concentration, thus driving the segment.

Moreover, intermittent feeding is recommended several times throughout the day, which may enhance muscle protein synthesis and thus is expected to increase its adoption. This feeding flow type also provides freedom during rehabilitation and other procedures and reduces the chances of diarrhea, which is further anticipated to boost segment growth.

However, the continuous feeding flow type segment is anticipated to grow at the highest CAGR over the forecast years. An increase in preference for continuous feeding flow as it is less labor-intensive for nursing staff and provides better Gastric Residual Volume (GRV) management is further supporting segment growth. In addition, the adoption of continuous feeding flow types for critically ill patients suffering from severe burns, cancer, respiratory failure, and heart conditions is also anticipated to boost segment growth over the forecast period.

Stage Insights

In 2021, the adult segment accounted for the highest revenue share of 88.6% based on stage. This segment is also anticipated to grow at the fastest CAGR over the coming years. The high share of the segment can be attributed to the increasing adoption of enteral tube feeding among adults suffering from several health conditions, such as Chronic Obstructive Pulmonary Diseases (COPDs), diabetes, cancer, stroke, dementia, and multiple sclerosis, and chronic liver disease. In addition, an increase in preference for continuous feeding for hospitalized adult patients requiring enteral nutrition therapy is also anticipated to boost segment growth.

Moreover, the growing adult patient population with functional gastrointestinal tract disorders benefitted from enteral nutrition via tube feeding to meet their nutritional requirements, which is further supporting segment growth. For instance, a study published in the Gastroenterology journal in 2021 reported that about 40% of adults suffer from a functional gastrointestinal disorder worldwide. In addition, an increase in preference for tube feeds among the adult population suffering from neurovascular disorders to improve nutritional status and enhance patients’ quality of life also positively impacts the market growth.

Indication Insights

In 2021, based on indications, the others segment followed by cancer care dominated with the highest revenue share of 43.0%. Tube feeding is preferred in several disease conditions, such as stroke, nausea, severe fatigue, neurological or movement disorders, gastrointestinal dysfunction or disease, etc., which, in turn, boosts segment growth.

In addition, the increase in cancer prevalence globally and the health conditions associated with this disease, such as fatigue, vomiting, and nausea, which make it difficult to eat, in turn, is anticipated to fuel the adoption of tube feeding. For instance, the data published by GLOBOCON in 2021 stated that there were about 19.3 million new cases of cancer in 2020 over the globe. Asia accounted for the highest share of cancer deaths with 58.3% and Europe accounted for about 22.8% of total cancer cases.

Furthermore, the orphan diseases segment is expected to grow at the fastest CAGR over the forecast years. This growth rate can be attributed to an increase in preference for clinical and nutrition management of rare or orphan diseases to improve quality of life and raise awareness about tube feeding for rare disease conditions.

Some of the major orphan diseases are cystic fibrosis, Duncan's syndrome, Lou Gehrig's disease, Madelung's disease, Tourette's syndrome, and acromegaly/gigantism. These diseases are associated with a high risk of malnutrition, which further drives the adoption of tube feeding to manage the condition.

End-User Insights

Based on end-user, the homecare segment accounted for the highest revenue share of 56.3% in 2021, and the segment is projected to grow at the fastest CAGR over the forecast period. An increase in the administration of enteral nutrition for patients who require long-term, life-sustaining care outside the hospital is anticipated to accelerate homecare segment growth. In addition, for many chronic diseases and conditions, tube feeding is the only option to feed patients, which is another key factor contributing to the growth of the segment.

For instance, according to a survey conducted in the U.K., about 187 patients were on home enteral tube feeding among 257 patients, which suggested that approximately 72% of patients were on enteral tube feeding at home. Furthermore, growing awareness to adopt enteral feeding formulas among patients suffering from chronic diseases at home-based healthcare settings is further anticipated to boost segment growth over the years. An increase in government initiatives to raise awareness about the utilization of enteral feeding systems or pumps for improving health conditions are some of the other factors supporting segment growth.

Regional Insights

By region, North America accounted for the highest revenue share of 28.9% in 2021. This revenue share can be attributed to an increase in the burden of chronic diseases, such as cancer, diabetes, and neurological conditions. In addition, increasing awareness among individuals in the region about the benefits of tube nutrition to manage their chronic health conditions is further expected to drive the market in this region.

Furthermore, an increase in the number of patients suffering from gastrointestinal disorders in the U.S. further drives the adoption of tube nutrition in North America. For instance, according to the Office of Disease Prevention and Health Promotion report, in the U.S., chronic diseases are the leading cause of death, i.e., 7 out of 10 deaths each year.

Furthermore, the fastest growth is anticipated from the Asia Pacific region during the forecast period owing to a large population, an increase in the number of chronic disease patients, and a rise in the incidence of malnutrition. In addition, the growing number of preterm births in Asian countries is also one of the major factors propelling regional growth.

According to World Health Organization (WHO), 60% of preterm birth cases are reported in Asia and sub-Saharan Africa. The top five countries with the largest number of preterm births are India, China, Nigeria, Pakistan, and Indonesia. Furthermore, an increase in awareness about better nutrition management and growing healthcare expenditure in many Asian countries, including Japan, China, India, and Singapore, are expected to drive the market in the forthcoming years.

Key Companies & Market Share Insights

The market players are looking forward to launching new innovative products to expand their product portfolio and global presence. The market is characterized by the presence of leading players with a strong global presence, a wider product portfolio, and improved financial performances. For instance, Abbott, one of the leading players, distributes and sells products in over 150 countries.

In addition, major companies are continuously focusing on R&D activities to develop new formulations as per patients’ needs. These companies are also seeking strategic collaborations with other players, in the form of partnerships and mergers, for expanding their product portfolios and leveraging their technological capabilities.

For instance, in July 2020, Baxter International, Inc. collaborated with VIPUN Medical to commercialize Gastric Monitoring System. This system featured a smart enteral feeding tube to measure stomach motility that helps clinicians in making better nutrition decisions in the ICU and other clinical settings. Some of the prominent players in the enteral feeding formulas market include:

• Abbott

• Danone SA

• Fresenius Kabi

• Nestlé

• Victus, Inc.

• Primus Pharmaceuticals, Inc.

• Meiji Holdings. Co., Ltd

• Rickett Benckiser Group Plc

Enteral Feeding Formulas Market Report Scope

Global Enteral Feeding Formulas Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2030. For this study, Grand View Research, Inc. has segmented the global enteral feeding formulas market report based on product, flow type, stage, indication, end-user, and region:

• Product Outlook (Revenue, USD Million, 2014 - 2030)

  • Standard formula

  • Disease-specific formula

• Flow Type Outlook (Revenue, USD Million, 2014 - 2030)

  • Intermittent feeding flow

  • Continuous feeding flow

• Stage Outlook (Revenue, USD Million, 2014 - 2030)

  • Adult

  • Pediatric

• Indication Outlook (Revenue, USD Million, 2014 - 2030)

  • Alzheimer’s

  • Nutrition Deficiency

  • Cancer Care

  • Diabetes

  • Chronic Kidney Diseases

  • Orphan Diseases

  • Dysphagia

  • Pain Management

  • Malabsorption/GI Disorder/Diarrhea

  • Others

• End-user Outlook (Revenue, USD Million, 2014 - 2030)

  • Hospitals

    • Cardiology

    • Neurology

    • Critical Care (ICU)

    • Oncology

    • Others

  • Home Care

• Sales Channel Outlook (Revenue, USD Million, 2014 - 2030)

  • Online Sales

  • Institutional Sales

  • Retail Sales

• Regional Outlook (Revenue, USD Million, 2014 - 2030 )

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • Italy

    • France

    • Spain

    • Russia

  • Asia-Pacific

    • Australia

    • China

    • Japan

    • South Korea

    • India

    • Singapore

    • New Zealand

  • Latin America

    • Mexico

    • Brazil

    • Argentina

  • Middle East Africa

    • South Africa

    • Saudi Arabia

    • UAE